The Pulmonary Inflammation Company

The mission of RS BioTherapeutics is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation. RS BioTherapeutics’ first investigational compound (RSBT-001) is a first-in-class therapeutic in development as an alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation including COPD, Idiopathic Pulmonary Fibrosis, Pulmonary Arterial Hypertension, and others. RSBT-001 reduces pulmonary inflammation by harnessing the immune modulating power of specific, anti-inflammatory cannabinoids and targeting the inflammatory cascade in the lungs at multiple levels. RS BioTherapeutics is targeting an IND filing for RSBT-001 in 2026.

Leadership Team

Our leadership team is comprised of industry leaders and specialists who are committed to the advancement of our vision and mission.

Therapeutic Expert Council

Learn more about the team of experts who are working with RS BioTherapeutics.

Our Advisors

Meet the individuals on our advisory team.

Contact Us


Join us in redefining the treatment of pulmonary inflammation. Invest in RS BioTherapeutics and lead the change!